TAK, US8740602052

Takeda stock gains Japan filing for psoriasis drug zasocitinib

Published on 11/13/2026 at 09:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda stock is in focus after a Japanese filing for zasocitinib covering three psoriasis indications. The move adds a fresh regulatory milestone.

Japan filing advances psoriasis program

Takeda filed a Japanese application for once-daily oral zasocitinib in three psoriasis indications.
The filing targets patients who have not responded adequately to existing treatments.
The application adds a regulatory milestone for Takeda's late-stage medicine pipeline.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical has filed in Japan for approval of zasocitinib, a once-daily oral selective tyrosine kinase 2 inhibitor, in three psoriasis indications. Pharma Japan reported the filing on Thursday, November 12, after Takeda submitted the application on Wednesday, November 11.

The application covers patients whose psoriasis has not responded adequately to existing treatments. The filing is a regulatory step rather than an approval, so commercial availability in Japan still depends on the review and decision process.

Zasocitinib moves into another review

Zasocitinib, also known as TAK-279, is intended to act on TYK2, an immune-system pathway relevant to inflammatory diseases. Takeda is developing the medicine as part of a broader late-stage pipeline focused on new products and future growth.

For investors, the Japanese application expands the regulatory path for the medicine beyond its existing development program. The filing may improve the visibility of a potential future launch, while the timing of any decision, the label granted by Japanese regulators and the eventual reimbursement terms remain important commercial factors.

Takeda stock traded at 19.50 euros on Lang & Schwarz at 09:27 CET on Friday, November 13, 2026.